The European Medicines Agency (EMA) concluded on Monday 25 October that a third dose of Moderna’s Covid-19 vaccine (Spikevax) could be considered for people aged 18 and over with a normal immune system.
Based on the data submitted, the EMA states that a booster dose of Spikevax six to eight months after the second dose does result in an increase in antibody levels in adults whose antibody levels had previously decreased. “The booster dose consists of half the dose used for the primary...